SCHEMBL6397287

SCHEMBL6397287

Cc1ccc(O)c(NC(=O)O)c1

nearest known ligand 0.69

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
KCNMA1 Q12791 4/20 0.69
GAA P10253 9/20 0.67
SMN1; SMN2 Q16637 3/20 0.67
MAPT P10636 2/20 0.67
NPC1 O15118 5/20 0.57
TP53 P04637 1/20 0.57
HTT P42858 3/20 0.54
CSNK2A1 P68400 1/20 0.53
RAB9A P51151 2/20 0.53
CA12 O43570 1/20 0.53
CA1 P00915 1/20 0.53
CA2 P00918 1/20 0.53
CA9 Q16790 1/20 0.53
POLB P06746 1/20 0.53
MAPK1 P28482 1/20 0.53
MEN1 O00255 2/20 0.52
KMT2A Q03164 2/20 0.52
PKM P14618 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1224549 0.86 KCNMA1 (0.62) KCNMA1GAASMN1; SMN2MAPTNPC1
SCHEMBL8006888 0.84 HPGD (0.72) KCNMA1GAASMN1; SMN2MAPTNPC1
SCHEMBL27877164 0.83 CXCR2 (0.67) KCNMA1GAASMN1; SMN2MAPTNPC1
SCHEMBL11850690 0.83 HPGD (0.70) KCNMA1GAASMN1; SMN2MAPTNPC1
SCHEMBL6029542 0.82 KCNMA1 (0.84) KCNMA1GAASMN1; SMN2MAPTNPC1
SCHEMBL10873010 0.82 KCNMA1 (1.00) KCNMA1GAASMN1; SMN2MAPTNPC1
SCHEMBL14363390 0.81 KCNMA1 (0.66) KCNMA1GAASMN1; SMN2MAPTNPC1
SCHEMBL12339789 0.81 KCNMA1 (0.57) KCNMA1GAASMN1; SMN2MAPTNPC1
SCHEMBL2605548 0.81 KCNMA1 (0.82) KCNMA1GAASMN1; SMN2MAPTNPC1
SCHEMBL14354719 0.81 GAA (0.72) KCNMA1GAASMN1; SMN2MAPTNPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8168650-B2 Therapeutic uses of bicyclic ligands of sigma 2 receptor WASHINGTON UNIVERSITY (US) 2012-05-01 US disclosed
US-20100048614-A1 THERAPEUTIC USES OF BICYCLIC LIGANDS OF SIGMA 2 RECEPTOR WASHINGTON UNIVERSITY (US) 2010-02-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100048614-A1 THERAPEUTIC USES OF BICYCLIC LIGANDS OF SIGMA 2 RECEPTOR SIGMAR1, TMEM97, BAD KCNMA1 1319/4885GAA 2640/4885SMN1; SMN2 2343/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.